Abstract:Background: In recent years, the incidence of insulin resistance is increasing, and it can cause a variety of Metabolic syndrome. Ginsenosides have been clinically proven to improve fat metabolism and reduce insulin resistance, but their components and mechanism of action are still unclear. Objective: Ginsenoside, a bioactive compound derived from ginseng, exhibits significant potential in treating obesity, diabetes, and metabolic disorders. Despite evidence supporting its efficacy in ameliorating insulin resistance (IR) in obesity, the specific bioactive components and underlying mechanisms remain obscure. In this study, we endeavored to elucidate the potential molecular targets and pathways influenced by ginsenoside Rh3 (GRh3) to ameliorate IR in liver tissue. We employed a comprehensive approach that integrates system pharmacology and bioinformatics analysis. Materials and methods: Our methodology involved the identification of candidate targets for GRh3 and the profiling of differentially expressed genes (DEGs) related to IR in individuals with insulin resistance. The coalescence of candidate targets and DEGs facilitated the construction of a "GRh3-targets-disease" network for each tissue type, ultimately yielding 38 shared target genes. Subsequently, we conducted pathway enrichment analysis, established protein-protein interaction (PPI) networks, and identified hub targets among the GRh3 targets and IR-related DEGs. Additionally, we conducted animal experiments to corroborate the role of these hub targets in the context of GRh3. Results: Our investigation identified a total of 38 overlapping targets as potential candidates. Notably, our analysis revealed crucial hub targets such as EGFR, SRC, ESR1, MAPK1, and CASP3, alongside implicated signaling pathways, including those related to insulin resistance, the FoxO signaling pathway, the PPAR signaling pathway, and the IL-17 signaling pathway. This study establishes a robust foundation for the mechanisms underlying GRh3's efficacy in mitigating IR. Furthermore, these results suggest that GRh3 may serve as a representative compound within the ginsenoside family. Conclusion: This study elucidates the potential molecular targets and associated pathways through which GRh3 ameliorates IR, showcasing its multifaceted nature, spanning multiple targets, pathways, and mechanisms. These findings establish a robust foundation for subsequent experimental inquiries and clinical applications.

Ginsenoside Re reduces insulin resistance through activation of PPAR-γ pathway and inhibition of TNF-α production

Ginsenoside Re Reduces Insulin Resistance Through Inhibition Of C-Jun Nh2-Terminal Kinase And Nuclear Factor-Kappa B

Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.

Protective effect on pancreatic β cells of α-glucosidase inhibitors screened from Rehmannia glutinosa

Ginsenoside Rb1 Promotes Adipogenesis in 3T3-L1 Cells by Enhancing PPARγ2 and C/EBPα Gene Expression

Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides.

Ginsenoside Rb1 and Compound K Improve Insulin Signaling and Inhibit ER Stress-Associated NLRP3 Inflammasome Activation in Adipose Tissue

Ginsenoside Rg1 Ameliorates Pancreatic Injuries Via the AMPK/mTOR Pathway in Vivo and in Vitro.

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Bioinformatics study of the potential therapeutic effects of ginsenoside Rh3 in reversing insulin resistance

Ginsenoside Rb3 Strengthens the Hypoglycemic Effect Through Ampk for Inhibition of Hepatic Gluconeogenesis

Anti-diabetic Effects of Panax Notoginseng Saponins and Its Major Anti-Hyperglycemic Components

Ginsenoside Rb1 facilitates adipocyte differentiation and inhibits lipolysis in 3T3-L1 adipocytes

Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis

UHPLC-MS-Based Serum and Urine Metabolomics Reveals the Anti-Diabetic Mechanism of Ginsenoside Re in Type 2 Diabetic Rats

Ginsenoside Re Attenuates High Glucose-Induced RF/6A Injury via Regulating PI3K/AKT Inhibited HIF-1α/VEGF Signaling Pathway

Ginsenoside CK inhibits obese insulin resistance by activating PPARγ to interfere with macrophage activation

Ginsenoside Rg3 ameliorates myocardial glucose metabolism and insulin resistance via activating the AMPK signaling pathway

Ginsenoside Rh1 Improves Type 2 Diabetic Nephropathy Through AMPK/PI3K/Akt-Mediated Inflammation and Apoptosis Signaling Pathway.

G-Rh4 improves pancreatic β-cells dysfunction in vivo and in vitro by increased expression of Nrf2 and its target genes

Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats.